natgillin/translations-raw huggingface dataset:
In two replicate 12 month studies in a total of 3,255 patients with COPD the incidence of bone fractures overall was low in all treatment groups, with a higher incidence in all Relvar Ellipta groups (2%) compared with the vilanterol 22 micrograms group (<1%). 
V dveh repliciranih 12-mesečnih študijah pri skupno 3.255 bolnikih s KOPB je bila celotna incidenca zlomov kosti majhna v vseh terapevtskih skupinah, a je bila večja v vseh skupinah z zdravilom Relvar Ellipta (2 %) kot v skupini s 22 mikrogrami vilanterola (< 1 %).
Vilanterol is primarily metabolised by O-dealkylation to a range of metabolites with significantly reduced 1- and 2-agonist activity. 
Vilanterol se presnovi predvsem z O-dealkilacijo v celo vrsto presnovkov, ki imajo bistveno manjše β1 in β2 agonistično delovanje.
Although there were more fractures in the Relvar Ellipta groups compared with the vilanterol 22 micrograms group, fractures typically associated with corticosteroid use (e.g., spinal compression/thoracolumbar vertebral fractures, hip and acetabular fractures) occurred in <1% of the Relvar Ellipta and vilanterol treatment arms. 
Čeprav je bilo v skupinah z zdravilom Relvar Ellipta več zlomov kot v skupini z 22 mikrogrami vilanterola, so se zlomi, ki so tipično povezani z uporabo kortikosteroidov (npr. spinalna kompresija/torakolumbalni zlomi vretenc, zlomi kolka in acetabula), tako v krakih z zdravilom Relvar Ellipta kot z vilanterolom pojavili pri < 1 %.
The apparent plasma elimination half-life of vilanterol following single inhaled administration of fluticasone furoate/vilanterol was, on average, 2.5 hours. 
Navidezni plazemski eliminacijski razpolovni čas vilanterola po enkratni inhalacijski uporabi kombinacije flutikazonfuroat/vilanterol je bil v povprečju 2,5 ure.
Do not block the air-vents with your fingers. 
Pazite, da ne boste s prsti prekrili rež za zrak.
if you think the above applies to you, don't use Relvar Ellipta until you have checked with your doctor. 
Če menite, da to velja za vas, ne uporabite zdravila Relvar Ellipta, dokler se ne posvetujete s svojim zdravnikom.
Do not open until ready to inhale. 
Ne odpirajte, dokler niste pripravljeni na inhaliranje.
Don't use this medicine if you are breastfeeding unless your doctor tells you that you can. 
Ne uporabite tega zdravila, če dojite, razen če vam je vaš zdravnik rekel, da ga lahko.
Fluticasone furoate is primarily metabolised through hydrolysis of the S-fluoromethyl carbothioate group to metabolites with significantly reduced corticosteroid activity. 
Flutikazonfuroat se presnovi predvsem s hidrolizo S-fluorometilkarbotioatne skupine v presnovke, ki imajo bistveno manjše kortikosteroidno delovanje.
Patients usually experience an improvement in lung function within 16-17 minutes of inhaling Relvar Ellipta. 
Bolnikom se pljučna funkcija po navadi izboljša v 16 do 17 minutah po inhaliranju zdravila Relvar Ellipta.
For an elderly subject (aged 84 years) with low bodyweight (35 kg) vilanterol AUC (0-24) is predicted to be 35% higher than the population estimate (subject with COPD aged 60 years and bodyweight of 70 kg), whilst Cmax was unchanged. 
(starost 84 let) z majhno telesno maso (35 kg) je predvideni AUC(0-24) vilanterola 35 % višji od populacijske ocene (bolnik s KOPB, star 60 let in s telesno maso 70 kg), Cmax pa se ni spremenila.
long-acting beta2-adrenergic agonists, such as salmeterol 
- dolgodelujoči agonisti adrenergičnih receptorjev beta2, kot npr. salmeterol.
The effective half-life for accumulation of vilanterol, as determined from inhalation administration of repeat doses of vilanterol 25 micrograms, is 16.0 hours in subjects with asthma and 21.3 hours in subjects with COPD. 
Efektivni razpolovni čas za kopičenje vilanterola, določen z inhalacijsko uporabo ponavljajočih se odmerkov 25 mikrogramov vilanterola, je pri osebah z astmo 16,0 ur in pri osebah s KOPB 21,3 ure.
Prior to randomization, subjects were required to discontinue previous COPD medications used at baseline, which included long-acting bronchodilators plus inhaled corticosteroids (28%), long-acting bronchodilators alone (11%) and inhaled corticosteroids alone (4%). 
Pred randomizacijo so morali bolniki prenehati uporabljati predhodna zdravila za KOPB, ki so jih jemali do izhodišča; to je vključevalo dolgodelujoče bronhodilatatorje in inhalirane glukokortikoide (28 %), dolgodelujoče bronhodilatatorje same (11 %) in inhalirane glukokortikoide same (4 %).
When you take the inhaler out of its tray, it will be in the ‘closed' position. 
Ko vzamete inhalator iz embalaže, bo v položaju "zaprto".
If symptoms arise in the period between doses, an inhaled, short-acting beta2-agonist should be used for immediate relief. 
Če se simptomi pojavijo v obdobju med odmerki, mora bolnik za takojšnje olajšanje uporabiti inhalirani kratkodelujoči agonist adrenergičnih receptorjev beta2.
184 micrograms [n=194]) both administered once daily compared with FP 500 micrograms twice daily [n=195]. 
[n = 197] in 184 mikrogramov FF [n = 194], obeh uporabljenih enkrat na dan, v primerjavi s FP 500 mikrogramov dvakrat na dan [n = 195].
Fluticasone furoate/vilanterol should not be used to treat acute asthma symptoms or an acute exacerbation in COPD, for which a short-acting bronchodilator is required. 
Flutikazonfuroat/vilanterol se ne sme uporabljati za zdravljenje simptomov akutne astme ali akutnega poslabšanja KOPB; za to je potreben kratkodelujoč bronhodilatator.
Prescribers should be aware that in patients with asthma, fluticasone furoate (FF) 100 micrograms once daily is approximately equivalent to fluticasone propionate (FP) 250 micrograms twice daily, while FF 200 micrograms once daily is approximately equivalent to FP 500 micrograms twice daily. 
Zdravniki, ki predpisujejo to zdravilo, morajo vedeti, da je pri bolnikih z astmo odmerek 100 mikrogramov flutikazonfuroata (FF) enkrat na dan približno enakovreden odmerku 250 mikrogramov flutikazonpropionata (FP) dvakrat na dan, odmerek 200 mikrogramov FF enkrat na dan pa je približno enakovreden odmerku 500 mikrogramov FP dvakrat na dan.
Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods. 
Med uporabo vseh inhalacijskih kortikosteroidov se lahko pojavijo sistemski učinki, zlasti med dolgotrajno uporabo velikih odmerkov.
The increase in fluticasone furoate exposure was associated with a 27% reduction in 0-24 hours weighted mean serum cortisol. 
Povečanje izpostavljenosti flutikazonfuroatu je spremljalo 27 % zmanjšanje utežene povprečne koncentracije kortizola v obdobju 0-24 ur.
Relvar Ellipta contains two active substances: fluticasone furoate and vilanterol. 
Zdravilo Relvar Ellipta vsebuje dve zdravilni učinkovini: flutikazonfuroat in vilanterol.
Fluticasone furoate and vilanterol represent two classes of medications (a synthetic corticosteroid and a selective, long-acting beta2-receptor agonist). 
Flutikazonfuroat in vilanterol predstavljata dve skupini zdravil (sintetičen kortikosteroid in selektiven, dolgodelujoč agonist adrenergičnih receptorjev beta2).
Serial FEV1 measurements were compared with pre-allergen challenge values taken after saline inhalation (baseline). 
Zaporedne meritve FEV1 so primerjali z vrednostmi pred provokacijo z alergenom, dobljene po inhaliranju fiziološke raztopine (izhodišče).
It may not be possible to taste or feel the medicine, even when using the inhaler correctly. 
Zdravila se morda ne bo ne okusilo, ne občutilo, tudi če se inhalator uporablja pravilno.
In the 12 months prior to the study, 61% of subjects reported no COPD exacerbations and 39% of subjects reported ≥1 moderate/severe COPD exacerbation. 
V 12 mesecih pred študijo je imelo poslabšanje KOPB 61 % bolnikov, 39 % pa jih je imelo ≥ 1 zmerno/hudo poslabšanje
Fluticasone furoate or vilanterol has no or negligible influence on the ability to drive and use machines. 
4.7 Vpliv na sposobnost vožnje in upravljanja strojev Flutikazonfuroat in vilanterol nimata vpliva ali imata zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
For patients with moderate or severe hepatic impairment the maximum dose is 92/22 micrograms (see section 4.4). 
Za bolnike z zmerno ali hudo okvaro jeter je najvišji odmerek 92/22 mikrogramov (glejte poglavje 4.4).
The pharmacologic effects of beta2-adrenoceptor agonist active substances, including vilanterol trifenatate, are at least in part attributable to stimulation of intracellular adenylate cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP). 
Farmakološke učinke agonistov adrenergičnih receptorjev beta2, vključno z vilanterolijevim trifenatatom, je mogoče vsaj deloma pripisati stimulaciji znotrajcelične adenilat-ciklaze, tj. encima, ki katalizira pretvorbo adenozin trifosfata (ATP) v ciklični 3', 5'-adenozin monofosfat (ciklični AMP).
Relvar Ellipta is for inhalation use only. 
Zdravilo Relvar Ellipta je namenjeno samo za inhalacijsko uporabo.
Symptoms come and go and include shortness of breath, wheezing, chest tightness and cough. 
Simptomi se pojavljajo in izginjajo; med njimi so kratka sapa, piskajoče dihanje, tiščanje v prsih in kašelj.
1 inhaler of 14 doses 1 inhaler of 30 doses 
1 inhalator s 14 odmerki 1 inhalator s 30 odmerki
The device does not need to be stored in the foil laminate tray once it has been opened. 
Pripomočka vam ni treba shranjevati v embalaži, potem ko ste jo že odprli.
Clinically significant drug interactions mediated by fluticasone furoate/vilanterol at clinical doses are considered unlikely due to the low plasma concentrations achieved after inhaled dosing. 
Klinično pomembna medsebojna delovanja z zdravili zaradi flutikazonfuroata/vilanterola v kliničnih odmerkih niso verjetna, ker je koncentracija v plazmi po inhaliranju nizka.
• inflammation of the lungs (bronchitis) 
• vnetje pljuč (bronhitis),
Both studies had a 4 week run-in period during which all subjects received open-label salmeterol/FP 50/250 twice daily to standardise COPD pharmacotherapy and stabilise disease prior to randomisation to blinded study medication for 52 weeks. 
Med obdobjem uvajanja so vsi bolniki odprto prejemali salmeterol/FP 50/250 dvakrat na dan za standardizacijo farmakoterapije KOPB in stabilizacijo bolezni pred randomizacijo v 52-tedensko obdobje slepljenega raziskovanega zdravila.
The 24-hour bronchodilator effect of fluticasone furoate/vilanterol was maintained throughout a one-year treatment period with no evidence of loss in efficacy (no tachyphylaxis). 
24-urni brohodilatacijski učinek flutikazonfuroata/vilanterola se je med enoletnim obdobjem zdravljenja ohranil in ugotovili niso nobenih znakov zmanjšanja učinkovitosti (tj. nobene tahifilaksije).
A clinical pharmacology study of fluticasone furoate/vilanterol showed that severe renal impairment (creatinine clearance <30mL/min) did not result in significantly greater exposure to fluticasone furoate or vilanterol or more marked corticosteroid or beta2-agonist systemic effects compared with healthy subjects. 
Klinična farmakološka študija flutikazonfuroata/vilanterola je pokazala, da huda okvara ledvic (očistek kreatinina < 30 ml/min) ne povzroči bistveno večje izpostavljenosti flutikazonfuroatu ali vilanterolu ali izrazitejših kortikosteroidnih ali beta2-agonističnih sistemskih učinkov v primerjavi z zdravimi preiskovanci.
The exposureadjusted rates (per 1000 treatment years) for all fracture events were 13.6, 12.8, 13.2, 11.5 respectively; fractures commonly associated with ICS use were 3.4, 3.9, 2.4, 2.1 respectively. 
Za izpostavljenost prilagojeni deleži (na 1000 let zdravljenja) so bili za vse zlome 13,6, 12,8, 13,2, 11,5 (v tem zaporedju) in za zlome, pogosto povezane z uporabo ICS 3,4, 3,9, 2,4, 2,1 (v tem zaporedju).
• increase in blood sugar (hyperglycaemia) 
• zamegljen vid, • povišanje sladkorja v krvi (hiperglikemija).
There is no relevant use of Relvar Ellipta in the paediatric population for the indication of COPD. 
Pediatrična populacija Zdravilo Relvar Ellipta ni primerno za uporabo v pediatrični populaciji za indikacijo KOPB.
If you have severe asthma, your doctor may decide that you should use one inhalation of the higher strength inhaler (184 micrograms fluticasone furoate and 22 micrograms of vilanterol). 
Če imate hudo astmo, vam lahko zdravnik predpiše uporabo ene inhalacije višje jakosti (184 mikrogramov flutikazonfuroata in 22 mikrogramov vilanterola).
The inhaler contains two aluminium foil laminate strips of 14 or 30 doses. 
V notranjosti inhalatorja sta dva laminatna trakova iz aluminija s 14 ali 30 odmerki.
Pharmacological and toxicological effects seen with fluticasone furoate or vilanterol in nonclinical studies were those typically associated with either glucocorticoids or beta2-agonists. 
Farmakološki in toksikološki učinki, ki so jih s flutikazonfuroatom ali vilanterolom zabeležili v nekliničnih študijah, so bili takšni, kot tipično spremljajo glukokortikoide ali agoniste adrenergičnih receptorjev beta2.
An overdose of fluticasone furoate/vilanterol may produce signs and symptoms due to the individual component's actions, including those seen with overdose of other beta2-agonists and consistent with the known inhaled corticosteroid class effects (see section 4.4). 
Preveliko odmerjanje flutikazonfuroata/vilanterola lahko povzroči znake in simptome, ki so posledica delovanja vsake od obeh sestavin, vključno z znaki in simptomi prevelikega odmerjanja drugih agonistov adrenergičnih receptorjev beta2 in skladnih z znanimi učinki inhaliranih kortikosteroidov (glejte poglavje
Effects seen following inhalation administration of fluticasone furoate in combination with vilanterol in rats were similar to those seen with fluticasone furoate alone. 
Učinki, ki so jih pri podganah zabeležili po inhalacijski uporabi flutikazonfuroata v kombinaciji z vilanterolom, so bili podobni kot s samim flutikazonfuroatom.
Patients usually experience an improvement in lung function within 15 minutes of inhaling Relvar Ellipta. 
Bolnikom se pljučna funkcija po navadi izboljša v 15 minutah po inhaliranju zdravila Relvar Ellipta.
Studies versus salmeterol/fluticasone propionate combinations 
Študije v primerjavi s kombinacijami salmeterola/flutikazonpropionata
Consistent with findings for other beta2 agonists, in lifetime inhalation studies vilanterol trifenatate caused proliferative effects in the female rat and mouse reproductive tract and rat pituitary gland. 
Skladno z izsledki pri drugih agonistih adrenergičnih receptorjev beta2 je vilanterolijev trifenatat v študijah vseživljenjskega vdihavanja povzročil proliferacijske učinke v reproduktivnem traktu podganjih in mišjih samic ter v podganji hipofizi.
If your breathing or wheezing gets worse straight after using this medicine, stop using it and get medical help immediately. 
Če se vam dihanje ali piskanje takoj po uporabi zdravila poslabša, zdravilo nehajte uporabljati in takoj poiščite zdravniško pomoč.
Fluticasone furoate was not genotoxic in a standard battery of studies and was not carcinogenic in lifetime inhalation studies in rats or mice at exposures similar to those at the maximum recommended human dose, based on AUC. 
Flutikazonfuroat ni bil genotoksičen v standardni skupini študij in ni bil kancerogen v študijah vseživljenjskega vdihavanja pri podganah ali miših pri izpostavljenostih, podobnih kot so izpostavljenosti
When the inhaler is used for the first time, there is no need to check that it is working properly, and to prepare it for use in any special way. 
Ob prvi uporabi inhalatorja bolniku ni treba preveriti, ali deluje pravilno in mu ga tudi ni treba posebej pripravljati za uporabo.
Slide the cover down until you hear a ‘click'. 
Pokrovček mora potisniti navzdol, dokler se ne zasliši "klik".
In subjects with asthma and subjects with COPD there are no recommended dose modifications. 
Pri preiskovancih z astmo in preiskovancih s KOPB ni priporočenih prilagoditev odmerka.
• Slide the cover upwards as far as it will go, to cover the mouthpiece. 
• Potisnite pokrovček navzgor, kolikor daleč gre, da boste pokrili ustnik.
The adjusted mean treatment difference of 22 mL (95% CI: -18, 63mL) between the groups was not statistically significant (p=0.282). 
Korigirana povprečna razlika med zdravljenjema 22 ml (95 % IZ: -18, 63 ml) med skupinama ni bila statistično značilna (p = 0,282).
The date should be added as soon as the inhaler has been removed from the tray. 
Ta datum morate zapisati takoj, ko inhalator vzamete iz embalaže.
Subjects had moderate COPD (mean percent post-bronchodilator screening FEV1 of 60% [SD = 6%]), and a history of, or an increased risk of cardiovascular disease. 
Bolniki so imeli zmerno KOPB (povprečni delež FEV1 po bronhodilatatorju ob presejanju 60 % [standardni odklon = 6 %] ter anamnezo kardiovaskularne bolezni ali večje tveganje za takšno bolezen.
There is no additional benefit of the 184/22 micrograms dose compared to the 92/22 micrograms dose and there is a potential increased risk of pneumonia and systemic corticosteroid-related adverse reactions (see sections 4.4 and 4.8). 
Odmerek 184/22 mikrogramov v primerjavi z odmerkom 92/22 mikrogramov nima dodatnih koristi, obstaja pa lahko večje tveganje za pljučnico in sistemske neželene učinke, povezane s kortikosteroidi (glejte poglavji 4.4 in
• swelling, sometimes of the face or mouth (angioedema) 
• kožni izpuščaj (koprivnica) ali rdečina, • otekanje, včasih obraza ali ust (angioedem),
On average, vilanterol Cmax is predicted to be 220 to 287% higher and AUC(0-24) comparable for those subjects from an Asian heritage compared with subjects from other racial groups. 
V povprečju je predvidena Cmax vilanterola pri preiskovancih azijskega porekla za 220 do 287 % večja, njegova AUC(0-24) pa primerljiva tisti pri preiskovancih drugih rasnih skupin.
The co-primary endpoints in both studies were weighted mean FEV1 from zero to 4 hours post-dose at Day 168 and change from baseline in pre-dose trough FEV1 at Day 169. 
Soprimarna opazovana dogodka v obeh študijah sta bila utežen povprečni FEV1 od 0 do 4 ure po odmerku 168. dan in sprememba najnižjega FEV1 pred odmerkom glede na izhodišče 169. dan.
Cardioselective beta-blocking medicinal products should be used with caution in patients with a history of bronchospasm. 
Kardioselektivne blokatorje adrenergičnih receptorjev beta je treba previdno uporabljati pri bolnikih, ki imajo v anamnezi bronhospazem.
Patients should not stop therapy with fluticasone furoate/vilanterol in asthma, without physician supervision since symptoms may recur after discontinuation. 
Bolniki zdravljenja astme ali KOPB s flutikazonfuroatom/vilanterolom ne smejo končati brez zdravniškega nadzora, ker se lahko simptomi po prenehanju ponovijo.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland GlaxoSmithKline (Ireland) Limited logo 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Irska GlaxoSmithKline (Ireland) Limited logo
If patients are inadequately controlled on Relvar Ellipta 92/22 micrograms, the dose can be increased to 184/22 micrograms, which may provide additional improvement in asthma control. 
Če bolniki z zdravilom Relvar Ellipta 92/22 mikrogramov bolezni nimajo ustrezno urejene, pride v poštev zvišanje odmerka na 184/22 mikrogramov; to lahko prinese dodatno izboljšanje urejenosti astme.
The higher strength of Relvar Ellipta (184 micrograms fluticasone furoate and 22 micrograms of vilanterol) is not suitable for the treatment of COPD. 
Višja jakost zdravila Relvar Ellipta (184 mikrogramov flutikazonfuroata in 22 mikrogramov vilanterola) ni primerna za zdravljenje KOPB.
If the dose counter does not count down as you hear the ‘click', the inhaler will not deliver medicine. 
Če se število na števcu odmerkov ne zmanjša, ko se zasliši ''klik'', inhalator ne bo oddal zdravila.
A clinical pharmacology study in healthy subjects with co-administered vilanterol and the potent P-gp and moderate CYP3A4 inhibitor verapamil did not show any significant effect on the pharmacokinetics of vilanterol. 
Klinična farmakološka študija s sočasno uporabo vilanterola in verapamila, ki je močan zaviralec P-gp in zmeren zaviralec CYP3A4, pri zdravih preiskovancih ni pokazala pomembnega vpliva na farmakokinetiko vilanterola.
There is insufficient information on the excretion of fluticasone furoate or vilanterol trifenatate and/or metabolites in human milk. 
Dojenje Podatkov o izločanju flutikazonfuroata oziroma vilanterolijevega trifenatata in/ali njunih presnovkov v materinem mleku pri človeku ni dovolj.
The most commonly reported adverse reactions with fluticasone furoate and vilanterol were headache and nasopharyngitis. 
Najpogosteje zabeležena neželena učinka flutikazonfuroata in vilanterola sta bila glavobol in nazofaringitis.
If you have any of the following symptoms after taking Relvar Ellipta stop taking this medicine and tell your doctor immediately. 
Če imate po jemanju zdravila Relvar Ellipta katerega koli od naslednjih simptomov, zdravilo takoj nehajte uporabljati in nemudoma obvestite svojega zdravnika:
Following intravenous dosing, both fluticasone furoate and vilanterol are extensively distributed with average volumes of distribution at steady state of 661 L and 165 L, respectively. 
Porazdelitev Po intravenski uporabi se flutikazonfuroat in vilanterol obširno porazdelita; povprečni volumen porazdelitve v stanju dinamičnega ravnovesja je za flutikazonfuroat 661 l in za vilanterol 165 l.
What Relvar Ellipta is and what it is used for 
Kaj je zdravilo Relvar Ellipta in za kaj ga uporabljamo
Close the inhaler and rinse your mouth 
Zaprite inhalator in si splaknite usta.
The 92/22 micrograms strength is used for the regular treatment of chronic obstructive pulmonary disease (COPD) in adults, and asthma in adults and adolescents 12 years and over. 
Jakost 92/22 mikrogramov se uporablja za zdravljenje kronične obstruktivne pljučne bolezni (KOPB) pri odraslih in za zdravljenje astme pri odraslih in mladostnikih, starih 12 let ali več.
Take one long, steady, deep breath in. 
Naredi naj en dolg, enakomeren, globok vdih.
Use Relvar Ellipta at the same time each day as it is effective over 24 hours It is very important that you use this medicine every day, as instructed by your doctor. 
Zdravilo Relvar Ellipta uporabljajte vsak dan ob istem času, saj učinkuje 24 ur.
In inhalation studies in rabbits, vilanterol trifenatate caused effects similar to those seen with other beta2 agonists (cleft palate, open eyelids, sternebral fusion and limb flexure/malrotation). 
V inhalacijskih študijah pri podganah je povzročil podobne učinke, kot se pojavljajo z drugimi agonisti adrenergičnih receptorjev beta2 (palatoshiza, odprte veke, sternebralna fuzija in fleksura/malrotacija udov).
Relvar Ellipta should not be used in conjunction with other long-acting beta2-adrenergic agonists or medicinal products containing longacting beta2-adrenergic agonists. 
Zdravila Relvar Ellipta se ne sme uporabljati skupaj z drugimi dolgodelujočimi agonisti adrenergičnih receptorjev beta2 ali z zdravili, ki vsebujejo dolgodelujoče agoniste adrenergičnih receptorjev beta2.
Read this before you start 
Pred začetkom uporabe preberite ta navodila.
Don't open the inhaler until you are ready to inhale a dose of medicine. 
Ne odpirajte inhalatorja, dokler niste pripravljeni za vdihanje odmerka zdravila.
The effects of age on the pharmacokinetics of fluticasone furoate and vilanterol were determined in phase III studies in COPD and asthma. 
Vplive starosti na farmakokinetiko flutikazonfuroata in vilanterola so preučili v študijah III. faze pri KOPB
Exposure-adjusted all-cause mortality per 100 patients/year (%/yr) was: fluticasone furoate/vilanterol, 3.1 %/yr; placebo, 3.5 %/yr; fluticasone furoate, 3.2 %/yr; and vilanterol, 3.4 %/yr. 
Za izpostavljenost korigirana umrljivost zaradi vseh vzrokov na 100 bolnik-let (%/bl) je bila med uporabo flutikazonfuroata/vilanterola 3,1 %/leto, placeba 3,5 %/leto, flutikazonfuroata 3,2 %/leto in vilanterola 3,4 %/leto.